108 related articles for article (PubMed ID: 16445828)
1. cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy.
Valente G; Manfroi F; Peracchio C; Nicotra G; Castino R; Nicosia G; Kerim S; Isidoro C
Br J Haematol; 2006 Mar; 132(5):560-70. PubMed ID: 16445828
[TBL] [Abstract][Full Text] [Related]
2. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
3. Changes in expression of anti-apoptotic protein, cFLIP, in granulosa cells during follicular atresia in porcine ovaries.
Matsuda-Minehata F; Goto Y; Inoue N; Manabe N
Mol Reprod Dev; 2005 Oct; 72(2):145-51. PubMed ID: 16010689
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and grading of non-Hodgkin's lymphomas on fine needle aspiration cytology.
Mathur S; Dawar R; Verma K
Indian J Pathol Microbiol; 2007 Jan; 50(1):46-50. PubMed ID: 17474258
[TBL] [Abstract][Full Text] [Related]
5. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways.
de Hooge AS; Berghuis D; Santos SJ; Mooiman E; Romeo S; Kummer JA; Egeler RM; van Tol MJ; Melief CJ; Hogendoorn PC; Lankester AC
Clin Cancer Res; 2007 Jan; 13(1):206-14. PubMed ID: 17200356
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
7. [Expression of cellular FLICE inhibitory protein (cFLIP) in endometrial adenocarcinoma].
Chen HX; Liu YJ; Li H; Wang ZS
Ai Zheng; 2004 Mar; 23(3):254-8. PubMed ID: 15025952
[TBL] [Abstract][Full Text] [Related]
8. MIB1 (Ki-67) expression in non-Hodgkin's lymphomas.
Kalogeraki A; Tzardi M; Panagiotides I; Koutsoubi K; Bolioti S; Rontogianni D; Stefanaki K; Zois E; Karidi E; Darivianaki K; Delides G; Kanavaros P
Anticancer Res; 1997; 17(1A):487-91. PubMed ID: 9066700
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies.
Zhao X; Qiu W; Kung J; Zhao X; Peng X; Yegappan M; Yen-Lieberman B; Hsi ED
Leuk Res; 2008 Feb; 32(2):275-85. PubMed ID: 17659339
[TBL] [Abstract][Full Text] [Related]
10. [Nucleolar organizer as a marker of malignancy grade and prognosis of non-Hodgkin's malignant lymphoma].
Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Tupitsyn NN; Sholokhova EN
Arkh Patol; 1996; 58(4):22-8. PubMed ID: 8967858
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
12. Caspase-8 and its inhibitors in RCCs in vivo: the prominent role of ARC.
Heikaus S; Kempf T; Mahotka C; Gabbert HE; Ramp U
Apoptosis; 2008 Jul; 13(7):938-49. PubMed ID: 18516683
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas.
Szczuraszek K; Mazur G; Jeleń M; Dziegiel P; Surowiak P; Zabel M
Anticancer Res; 2008; 28(2A):1113-8. PubMed ID: 18507062
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of procaspase-3 and its clinical significance in childhood non-Hodgkin lymphomas.
Wrobel G; Maldyk J; Kazanowska B; Rapala M; Maciejka-Kapuscinska L; Chaber R
Pediatr Dev Pathol; 2011; 14(3):173-9. PubMed ID: 20722551
[TBL] [Abstract][Full Text] [Related]
16. AgNORs predictive value of prognosis in non-Hodgkin's lymphoma according to the Kiel classification.
Jakić-Razumović J; Petrovecki M; Dominis M
Mod Pathol; 1995 Feb; 8(2):143-9. PubMed ID: 7777474
[TBL] [Abstract][Full Text] [Related]
17. [Malignant non-Hodgkin's lymphoma of the joint. Report of two cases, review of the literature and problems of classification].
Krüger R; Oden J; de Leon F; Dürr W
Unfallchirurg; 1993 Oct; 96(10):556-62. PubMed ID: 8235678
[TBL] [Abstract][Full Text] [Related]
18. Anti-apoptotic activity of porcine cFLIP in ovarian granulosa cell lines.
Matsuda-Minehata F; Goto Y; Inoue N; Sakamaki K; Chedrese PJ; Manabe N
Mol Reprod Dev; 2007 Sep; 74(9):1165-70. PubMed ID: 17594695
[TBL] [Abstract][Full Text] [Related]
19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
20. Targeting cellular FLICE-like inhibitory protein as a novel approach to the treatment of Hodgkin's lymphoma.
Dutton A; Burns AT; Young LS; Murray PG
Expert Rev Anticancer Ther; 2006 Jun; 6(6):911-9. PubMed ID: 16761935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
